In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie is one of the better pharmaceutical stocks on the scene, buttressed by a strong product lineup and a promising ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

Emraclidine, a potential treatment for schizophrenia, is expected to yield Phase 2 registrational data by the end of 2024. If successful, AbbVie plans to file with the FDA in 2025 for a potential ...

after-tax impairment charge related to its investigational antipsychotic drug emraclidine that hasn't been included in management's guidance. AbbVie is one of the better pharmaceutical stocks on ...